AGM
CRBP icon

Alpine Global Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Alpine Global Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,621
Closed -$255K – 342
2020
Q1 		$255K Buy
+1,621
New +$274K 0.05% 148

Other funds holding CRBP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alpine Global Management's CRBP Position: Q2 2020 in Review

Alpine Global Management sold out of Corbus Pharmaceuticals (CRBP) in Q2 2020, closing a stake of 1,621 shares — an estimated $255K sold.

Alpine Global Management first reported a position in CRBP in Q1 2020 and held it in 1 quarter. The position peaked at $255K in Q1 2020. 140 funds tracked by Wall St. Rank hold CRBP as of Q2 2020.

  • Alpine Global Management reported no remaining Corbus Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Alpine Global Management sold 1,621 Corbus Pharmaceuticals shares in Q2 2020, an estimated $255K.
  • Alpine Global Management first reported a position in Corbus Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Alpine Global Management's Corbus Pharmaceuticals position peaked at $255K in Q1 2020.
  • 140 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2020.

Based on Alpine Global Management's 13F filing for Q2 2020, filed 14 Aug 2020.